Chen Jui-Cheng, Chen Chun-Ming, Aoh Yu, Cheng Yu-Kai, Lu Ming-Kuei, Tsai Chon-Haw
Neuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan.
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Eur J Neurol. 2025 Sep;32(9):e70345. doi: 10.1111/ene.70345.
Stepwise dual-target MR-guided Focused Ultrasound (dtMRgFUS) is a novel treatment for Parkinson's disease (PD), targeting both Ventral Intermediate Nucleus (VIM) and the pallidothalamic tract (PTT). While previous studies have demonstrated its 12-month efficacy, this study focuses on the immediate effects of additional PTT lesioning after VIM ablation.
Twenty patients (age 69.3 ± 8.9 years) with both tremor and akinetic rigidity received dtMRgFUS when they were off medications, with a series of primary and secondary outcome measures on the table. We performed unilateral VIM first, with subsequent ipsilateral PTT ablation in the same session. The primary outcomes were the off-status sub-score of the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) and the Clinical Rating Scale for Tremor (CRST). In addition, we compared the outcome changes from the baseline to the first VIM treatment with the changes from VIM treatment to the subsequent PTT treatment.
During the procedure, the severity of tremor, rigidity, and bradykinesia improved significantly (all p < 0.05 by paired t-test) after both VIM and PTT treatment. Notably, major improvement of parameters was noted after VIM lesioning (all p < 0.02 by paired t-test), except for rigidity, which showed significant changes immediately after PTT lesioning (p < 0.02 by paired t-test).
These findings highlight the immediate therapeutic impact of PTT lesioning following VIM lesioning in the same treatment session, reinforcing its role as a crucial add-on target for managing refractory PD symptoms beyond tremor. This dtMRgFUS approach offers a more comprehensive motor benefit, particularly for patients with rigidity.
逐步双靶点磁共振引导聚焦超声(dtMRgFUS)是一种治疗帕金森病(PD)的新方法,同时靶向腹中间核(VIM)和苍白球丘脑束(PTT)。虽然先前的研究已经证明了其12个月的疗效,但本研究重点关注VIM消融后额外PTT损伤的即时效应。
20例(年龄69.3±8.9岁)伴有震颤和运动不能性强直的患者在未服药状态下接受dtMRgFUS治疗,并进行了一系列主要和次要结局测量。我们先进行单侧VIM消融,然后在同一次治疗中对同侧PTT进行消融。主要结局指标为帕金森病统一评分量表第三部分(UPDRS-III)的未服药状态子评分和震颤临床评分量表(CRST)。此外,我们比较了从基线到首次VIM治疗的结局变化与从VIM治疗到后续PTT治疗的结局变化。
在手术过程中,VIM和PTT治疗后震颤、强直和运动迟缓的严重程度均显著改善(配对t检验,均p<0.05)。值得注意的是,VIM损伤后参数有显著改善(配对t检验,均p<0.02),除了强直,其在PTT损伤后立即出现显著变化(配对t检验,p<0.02)。
这些发现突出了在同一次治疗中VIM损伤后PTT损伤的即时治疗效果,强化了其作为治疗除震颤外难治性PD症状的关键附加靶点的作用。这种dtMRgFUS方法提供了更全面的运动益处,特别是对伴有强直的患者。